Tildrakizumab: short‐term efficacy and safety in real clinical practice-Reference-Cited by-同舟云学术

Tildrakizumab: short‐term efficacy and safety in real clinical practice

Published:2021-10-11 Issue: Volume: Page:
ISSN:0011-9059
Container-title:International Journal of Dermatology
language:en
Short-container-title:Int J Dermatology

Author:

Galán‐Gutierrez Manuel¹,Rodriguez‐Fernandez Freire Lourdes²,Ruiz‐Villaverde Ricardo³^ORCID

Affiliation:

1. Dermatology Unit Hospital Universitario Reina Sofia, IMIBIC. Universidad de Córdoba Córdoba Spain

2. Dermatology Unit Hospital Universitario Virgen del Rocio Sevilla Spain

3. Dermatology Unit Hospital Universitario San Cecilio Instituto de Investigación Biosanitaria ibs Granada Spain

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.15840

Reference5 articles.

1. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

2. Comparison of psoriasis guidelines for use of IL‐23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review;Ghamrawi RI;J Dermatolog Treat,2020

3. A Systematic literature review and Bucher indirect comparison: Tildrakizumab versus Guselkumab;Du Jardin KG;J Health Econ Outcomes Res,2020

4. Guselkumab: Short‐term effectiveness and safety in real clinical practice

5. Risankizumab: A pilot study of short‐term effectiveness and safety in real clinical practice

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A 3-Year Experience with Tildrakizumab Treatment for Patients with Plaque Psoriasis in Clinical Practice;Dermatology and Therapy;2024-08-27

2. Short‐term efficacy of tildrakizumab on difficult‐to‐treat areas: a real‐world experience;International Journal of Dermatology;2024-07-12

3. Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018–2023;Frontiers in Pharmacology;2024-07-10

4. Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis;Dermatology Practical & Conceptual;2023-10-31

5. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group;Journal of the European Academy of Dermatology and Venereology;2023-09